Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs shamQoL · adults with GA due to AMD1 finding from 1 reviewComplement inhibitors for age‐related macular degeneration 2023 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 1003 participantsModerate